Category - Developments

Developments

AIM signs Phase 3 design deal for Ampligen in pancreatic cancer

AIM ImmunoTech (NYSE American: AIM) has announced the signing of an agreement with Thermo Fisher Scientific’s (NYSE: TMO) PPD clinical research business to design its Phase 3 clinical trial for Ampligen in the treatment...

March 2, 2026

Developments

Zomedica expands distribution with Moichor partnership

Zomedica (OTCQB: ZOMDF) has entered into a commercial distribution agreement with closely held Moichor, a veterinary reference and point-of-care laboratory service, to expand its distribution of TRUVIEW(R) digital...

February 25, 2026

Developments

Tiziana announces positive new biomarkers for nasal foralumab

Tiziana Life Sciences (NASDAQ: TLSA) has announced new biomarker data from a late-breaking poster presented by investigators from Brigham and Women’s Hospital, Boston, showing nasal foralumab downregulates cerebrospinal...

February 25, 2026

Developments

BioRestorative bolsters global protection for potential GLP-1 alternative ThermoStem

BioRestorative Therapies (NASDAQ: BRTX) has announced that IP Australia has granted Patent Application No. 2020265664, covering 3D brown adipose-derived stem cell aggregates and their methods—offering broad protection...

February 24, 2026

Developments

FDA grants QIDP for Armata’s AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted AP-SA02 Qualified Infectious Disease Product (QIDP) designation for intravenous use in the adjunct treatment of complicated bacteremia...

February 23, 2026

Developments

C4 doses first patient in Phase 2 trial of cemsidomide in RRMM

C4 Therapeutics (NASDAQ: CCCC) has announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple...

February 23, 2026

Developments

Acrivon launches internal CLIA-certified lab

Acrivon Therapeutics (NASDAQ: ACRV) has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in...

February 18, 2026

Developments

Lipocine Completes Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression

Lipocine (NASDAQ: LPCN) has announced that the last patient has completed the final study visit in the Phase 3 trial of its oral brexanolon, LPCN 1154, for the treatment of postpartum depression (PPD). According to...

February 18, 2026

Developments

IP Australia grants Klotho 18 claims for s-KL

Klotho Neurosciences (NASDAQ: KLTO) has announced that IP Australia has accepted 18 claims within its patent application covering the composition and use of its human secreted Klotho protein, s-KL isoform. The patent...

February 18, 2026

Developments

Bioxytran reports positive Phase 2 data for ProLectin-M

Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with...

February 13, 2026

Category - Developments

Subscribe